International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma

Conditions

Ewing Sarcoma

Brief summary

iEuroEwing-SR: Analysis of EFS, iEuroEwing-SR-RT: Analysis of the occurrence of acute skin toxicity CTCAE grade ≥3 during radiotherapy, iEuroEwing-HR: Analysis of EFS

Detailed description

iEuroEwing-SR part: Investigation if the maintenance therapy with VinoCyc in a randomised design compared to the standard VDC/IE treatment alone improves overall survival (OS) since randomisation 2, aiming at a 10% increase, and whether the 3-year OS improves compared to historical controls., iEuroEwing-SR-RT part: Investigation if a higher dose of radiation improves local control since randomisation 1 and if a higher dose of radiation improves EFS and OS since randomisation 1., iEuroEwing-HR part: Investigation if the maintenance therapy with VinoCyc in a randomised design compared to the standard VDC/IE treatment alone improves OS, aiming at a 15% increase, and whether the 3-year OS improves compared to historical controls., Toxicity / Safety, Survival outcome, Quality of life, Time to diagnosis, Cancer predisposition, Correlation of histopathological, Biology of Ewing sarcoma

Related papers

No related papers found yet.

Interventions

DRUGFILGRASTIM

DRUGMESNA

DRUGIFOSFAMIDE

DRUGCYCLOPHOSPHAMIDE

DRUGDOXORUBICIN

DRUGETOPOSIDE

DRUGVINORELBINE

DRUGVINCRISTINE SULFATE

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
iEuroEwing-SR: Analysis of EFS, iEuroEwing-SR-RT: Analysis of the occurrence of acute skin toxicity CTCAE grade ≥3 during radiotherapy, iEuroEwing-HR: Analysis of EFS	—

Secondary

Measure	Time frame
iEuroEwing-SR part: Investigation if the maintenance therapy with VinoCyc in a randomised design compared to the standard VDC/IE treatment alone improves overall survival (OS) since randomisation 2, aiming at a 10% increase, and whether the 3-year OS improves compared to historical controls., iEuroEwing-SR-RT part: Investigation if a higher dose of radiation improves local control since randomisation 1 and if a higher dose of radiation improves EFS and OS since randomisation 1., iEuroEwing-HR part: Investigation if the maintenance therapy with VinoCyc in a randomised design compared to the standard VDC/IE treatment alone improves OS, aiming at a 15% increase, and whether the 3-year OS improves compared to historical controls., Toxicity / Safety, Survival outcome, Quality of life, Time to diagnosis, Cancer predisposition, Correlation of histopathological, Biology of Ewing sarcoma	—

Measure

Time frame

iEuroEwing-SR part: Investigation if the maintenance therapy with VinoCyc in a randomised design compared to the standard VDC/IE treatment alone improves overall survival (OS) since randomisation 2, aiming at a 10% increase, and whether the 3-year OS improves compared to historical controls., iEuroEwing-SR-RT part: Investigation if a higher dose of radiation improves local control since randomisation 1 and if a higher dose of radiation improves EFS and OS since randomisation 1., iEuroEwing-HR part: Investigation if the maintenance therapy with VinoCyc in a randomised design compared to the standard VDC/IE treatment alone improves OS, aiming at a 15% increase, and whether the 3-year OS improves compared to historical controls., Toxicity / Safety, Survival outcome, Quality of life, Time to diagnosis, Cancer predisposition, Correlation of histopathological, Biology of Ewing sarcoma

—

Countries

Austria, Belgium, Finland, Germany, Greece, Hungary, Poland, Sweden

Outcome results

None listed